September 17, 2020

A New Option for Patients with RET Fusion-Positive NSCLC Demonstrates Safety and Efficacy

Selpercatinib beats others in ORR, PFS, safety

17-PUL-3761-Almeida-Hero-Image-650x450pxl

The selective RET inhibitor selpercatinib is safe and effective in both treated and treatment-naïve patients with RET fusion-positive non-small cell lung cancer (NSCLC), according to the results of a phase 1/2 clinical trial recently published in New England Journal of Medicine. RET fusions have been identified in 1% to 2% of NSCLC cases and have been associated with a high risk of developing brain metastases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“We have kinase inhibitors that inhibit the RET proto-oncogene,” says Nathan Pennell, MD, PhD, coauthor of the study and Director of Cleveland Clinic Cancer Center’s Lung Cancer Medical Oncology program, “but the clinical benefit from these was modest at best for RET fusion-positive patients. The introduction of selpercatinib three years ago changed the game a bit, and now we have some early results showing promise.”

Study methods and results

Researchers enrolled both treatment-naïve and platinum chemotherapy-treated patients with advanced RET fusion-positive NSCLC in this first-in-human, global, multisite trial. They sought to measure objective response rate (ORR) as well as response duration, progression-free survival (PFS) and safety. They enrolled 105 patients who had undergone treatment and 39 treatment-naïve patients. Eleven patients overall had central nervous system (CNS) metastasis at enrollment.

The ORR in patients with prior treatment was 64% (95% CI, 54 to 73) with a median duration of response of 17.5 months (95% CI, 12.0 to NE) and 63% of responses maintained at a median 12.1 month follow up. The ORR in treatment-naïve patients was 85% (95% CI, 70 to 94), and 90% of patients had maintained responses at 6 months follow up. The intracranial ORR in patients with CNS metastasis was 91% (95% CI, 59 to 100).

Advertisement

“These are very encouraging results, superior to anything we’ve seen with multikinase inhibitors for these patients,” says Dr. Pennell, “and compare nicely to other targeted therapies for NSCLCs with oncogenic drivers such as EGFR mutations.”

In terms of safety, a few grade ≥ 3 adverse events occurred, including hypertension (14%), alanine aminotransferase increase (13%), aspartate aminotransferase increase (10%), hyponatremia (6%) and lymphopenia (6%), with four patients (3%) discontinuing treatment.

Selpercatinib a superior option

Selpercatinib (LOXO-292) is a novel, highly selective small molecule RET inhibitor that showed nanomolar potency against several RET alterations in experimental models, while sparing non-RET kinases and non-kinases. The drug penetrates the CNS, with demonstrated antitumor activity in the brain in preclinical models. Before the advent of selpercatinib, the multikinase inhibitor cabozantinib was often patients’ best option, with an ORR of 28% and median PFS of only six months. In May, the Federal Drug Administration approved selpercatinib for use in RET fusion-positive lung and thyroid cancers.

Advertisement

“This is a big win for the 10,000 or so RET fusion-positive NSCLC patients diagnosed across the globe each year,” says Dr. Pennell. “We are cautiously optimistic as we begin phase 3 trials.”

Related Articles

22-CNR-IV-Drip-CQD-Hero-650×450-1
April 20, 2022
Combination Chemo-Immunotherapy Appears to Improve Outcomes in Muscle-Invasive Bladder Cancer

New results from the BLASST-1 trial show increases in downstaging and relapse-free survival

Mammary carcinoma with lobular features. Breast cancer
April 12, 2022
MRI May Be Best Tool for Tumor Staging and Detecting Bilateral Disease in Invasive Lobular Carcinoma

Study highlights value of preoperative imaging to guide surgical decision-making

rt-breast_650x450
July 1, 2021
Designing an Optimal Breast Cancer Radiation Protocol

How a novel tissue marker makes a difference

PrimaryPulmonaryCarcinoid
June 29, 2021
Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC

Model identifies target OS at which economic benefits of treatment outpace placebo

650×450-Prostate-Cancer
June 25, 2021
Upfront Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Setting a new benchmark for control arm estimates

650×450-bladder
May 24, 2021
Combination Maintenance Therapy in Metastatic Urothelial Cancer

In search of improved outcomes for patients

Ad